American Century Companies Inc. Cuts Position in Boston Scientific Corporation $BSX

Key Points

• American Century Companies Inc. reduced its stake in Boston Scientific by 13.4%, now holding approximately 3.89 million shares valued at $392 million.
• Boston Scientific reported a 22.8% increase in quarterly revenue to $5.06 billion, exceeding analyst expectations for the quarter.
• A majority of the company's stock, 89.07%, is currently owned by institutional investors, reflecting strong institutional support.

American Century Companies Inc. reduced its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,887,378 shares of the medical equipment provider's stock after selling 601,445 shares during the quarter. American Century Companies Inc. owned 0.26% of Boston Scientific worth $392,159,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. HM Payson & Co. grew its stake in Boston Scientific by 1.4% in the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after buying an additional 98 shares during the last quarter. Baldwin Investment Management LLC grew its stake in Boston Scientific by 1.2% in the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock valued at $781,000 after buying an additional 102 shares during the last quarter. Park Square Financial Group LLC grew its stake in Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after buying an additional 103 shares during the last quarter. HHM Wealth Advisors LLC grew its stake in Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after buying an additional 103 shares during the last quarter. Finally, Evergreen Capital Management LLC grew its stake in Boston Scientific by 1.7% in the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock valued at $565,000 after buying an additional 106 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock valued at $35,976,603 over the last three months. 0.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a report on Wednesday, May 28th. Barclays increased their price target on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Oppenheimer increased their price target on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a research report on Thursday, July 24th. Finally, UBS Group increased their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and an average target price of $117.50.

Boston Scientific Trading Up 0.6%

Boston Scientific stock traded up $0.5940 during mid-day trading on Tuesday, hitting $103.6440. The company's stock had a trading volume of 4,617,923 shares, compared to its average volume of 7,573,114. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a market cap of $153.57 billion, a price-to-earnings ratio of 61.69, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. The business has a 50 day moving average price of $103.62 and a 200-day moving average price of $102.09. Boston Scientific Corporation has a 12 month low of $78.08 and a 12 month high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.